Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H17ClN6O3 |
Molecular Weight | 388.808 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C(=O)O[C@H]2N(C(=O)C3=C2N=CC=N3)C4=CC=C(Cl)C=N4
InChI
InChIKey=GBBSUAFBMRNDJC-MRXNPFEDSA-N
InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m1/s1
Molecular Formula | C17H17ClN6O3 |
Molecular Weight | 388.808 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/7905394Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1818054 | https://www.ncbi.nlm.nih.gov/pubmed/17870541 | https://www.ncbi.nlm.nih.gov/pubmed/11902799 | https://www.ncbi.nlm.nih.gov/pubmed/12404712 | http://www.who.int/medicines/areas/quality_safety/4.6ZopicloneCritReview.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7905394
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1818054 | https://www.ncbi.nlm.nih.gov/pubmed/17870541 | https://www.ncbi.nlm.nih.gov/pubmed/11902799 | https://www.ncbi.nlm.nih.gov/pubmed/12404712 | http://www.who.int/medicines/areas/quality_safety/4.6ZopicloneCritReview.pdf
(R)-Zopiclone is the (R)-enantiomer of benzodiazepine modulator Zopiclone. (S)-Zopiclone binding at benzodiazepine recognition sites is about 50-fold higher than of the (R)-zopiclone, and the pharmacokinetics of the enantiomers varies between individuals differently. In rats, there is no stereo conversion from (S)- to (R)-Zopiclone, whereas (R)-Zopiclone converts to (S)-Zopiclone, which is preferentially distributed into the brain. (R)-Zopiclone is known to have sedative and anxiolytic effects and as well as effects towards locomotor activity reduction.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25298123 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugs.com/mmx/zopiclone.html |
Primary | LUNESTA Approved UseZopiclone is indicated for the short-term treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Since sleep disturbances may be the presenting symptom of a physical and/or psychiatric disorder, the patient should be carefully evaluated before pharmacologic treatment is initiated. Insomnia that continues after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness. Launch Date2004 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/zopiclone.html
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/7905394
RS-Zopiclone: Oral, 5 mg to 7.5 mg at bedtime.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16399882
To study the effects of Zopiclone , GABA currents were repeatedly elicited by puffer application of 3 mkM GABA every 12 s, and test substances were applied by bath perfusion. A pressurized (10 p.s.i.) puffer pipette (~2 mkm tip diameter) was positioned near the recorded cell, and GABA (3 mkM) was applied by opening a computer-controlled solenoid valve (50–100 ms). This activated a peak inward current (200–2000 pA) that rapidly decayed. Because the small volume of GABA released from the puffer pipette was rapidly diluted in the external bath, the neurons were exposed to a maximum concentration of <3 mkM GABA. This is less than the EC50 of GABA for native and cloned GABAA receptors and provided a reliable starting point to measure potentiation of the current by positive allosteric modulators. Drugs were applied for 3 min (15 evoked GABA currents), which was sufficient for an equilibrium response to be established. Drugs were washed out for at least 3 min. If the GABA current recovered to predrug control amplitude, a higher concentration of drug was applied
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:12:15 GMT 2023
by
admin
on
Sat Dec 16 11:12:15 GMT 2023
|
Record UNII |
7A997Q53NR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID40160758
Created by
admin on Sat Dec 16 11:12:15 GMT 2023 , Edited by admin on Sat Dec 16 11:12:15 GMT 2023
|
PRIMARY | |||
|
941731
Created by
admin on Sat Dec 16 11:12:15 GMT 2023 , Edited by admin on Sat Dec 16 11:12:15 GMT 2023
|
PRIMARY | |||
|
7A997Q53NR
Created by
admin on Sat Dec 16 11:12:15 GMT 2023 , Edited by admin on Sat Dec 16 11:12:15 GMT 2023
|
PRIMARY | |||
|
138680-08-7
Created by
admin on Sat Dec 16 11:12:15 GMT 2023 , Edited by admin on Sat Dec 16 11:12:15 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|